Brokerages expect Achieve Life Sciences, Inc. (NASDAQ:ACHV – Get Rating) to post earnings of ($0.89) per share for the current quarter, Zacks reports. Zero analysts have provided estimates for Achieve Life Sciences’ earnings. Achieve Life Sciences reported earnings per share of ($1.30) in the same quarter last year, which indicates a positive year over year growth rate of 31.5%. The firm is scheduled to issue its next quarterly earnings results on Thursday, May 12th.
On average, analysts expect that Achieve Life Sciences will report full year earnings of ($2.76) per share for the current financial year, with EPS estimates ranging from ($3.50) to ($2.04). For the next fiscal year, analysts forecast that the business will post earnings of ($2.49) per share, with EPS estimates ranging from ($3.53) to ($1.45). Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow Achieve Life Sciences.
Achieve Life Sciences (NASDAQ:ACHV – Get Rating) last posted its earnings results on Thursday, March 10th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.69) by ($0.07). During the same quarter last year, the company earned ($1.11) EPS.
Shares of ACHV stock opened at $6.73 on Friday. Achieve Life Sciences has a 1 year low of $6.24 and a 1 year high of $12.95. The firm’s 50 day moving average is $7.60 and its 200-day moving average is $7.84. The firm has a market capitalization of $63.62 million, a price-to-earnings ratio of -1.45 and a beta of 1.19.
A number of institutional investors have recently added to or reduced their stakes in ACHV. Oppenheimer & Co. Inc. increased its holdings in Achieve Life Sciences by 8.7% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 25,000 shares of the biopharmaceutical company’s stock valued at $213,000 after buying an additional 2,000 shares during the period. LPL Financial LLC raised its holdings in Achieve Life Sciences by 4.7% during the third quarter. LPL Financial LLC now owns 72,000 shares of the biopharmaceutical company’s stock worth $612,000 after buying an additional 3,200 shares during the last quarter. Perkins Capital Management Inc. grew its stake in shares of Achieve Life Sciences by 2.9% in the 4th quarter. Perkins Capital Management Inc. now owns 174,600 shares of the biopharmaceutical company’s stock worth $1,358,000 after acquiring an additional 5,000 shares in the last quarter. BlackRock Inc. grew its position in Achieve Life Sciences by 455.6% during the fourth quarter. BlackRock Inc. now owns 15,207 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 12,470 shares during the period. Finally, Advisory Services Network LLC bought a new position in Achieve Life Sciences during the third quarter valued at about $111,000. 35.86% of the stock is owned by institutional investors and hedge funds.
Achieve Life Sciences Company Profile (Get Rating)
Achieve Life Sciences, Inc is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products includes cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider Achieve Life Sciences, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Achieve Life Sciences wasn’t on the list.
While Achieve Life Sciences currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.